Form 4: Tenax Therapeutics CFO Receives Equity Grant

Tenax Therapeutics CFO Thomas R. Staab II was granted 10,000 restricted shares and 450,000 stock options.

Summary

• Thomas R. Staab II, Chief Financial Officer of Tenax Therapeutics, Inc., received an equity compensation package on May 11, 2026.
• The grant includes 10,000 shares of restricted common stock.
• The grant includes 450,000 stock options with an exercise price of $11.95 per share.
• The restricted stock vests over a one-year period, while the options vest over a four-year period.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is expected behavior for a publicly traded company.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value.
• The multi-year vesting schedules for both restricted stock and options serve as a retention mechanism for key management.

Negatives

• The issuance of 450,000 options creates potential future dilution for existing shareholders.

Risks

• Continued employment is a prerequisite for the vesting of both the restricted stock and the stock options.
• The value of the granted options is dependent on the future market performance of Tenax Therapeutics common stock exceeding the $11.95 strike price.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation.

Management Comments

• No specific management commentary was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives are standard practice in the biotechnology sector to ensure leadership retention and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a four-year vesting schedule for stock options is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• The combination of restricted stock and options is a common compensation structure for CFOs in small-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of the granted stock options.

Next Steps

• Vesting of 25% of restricted stock on May 21, 2026.
• Vesting of 25% of stock options on May 11, 2027.

Key Dates

Keywords

Tenax Therapeutics, TENX, Form 4, Insider Trading, Equity Compensation, CFO, Stock Options